Previous 10 | Next 10 |
The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Corporate Presentation - Slideshow
Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...
Summary Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts. Data shared in June for CART-ddBCMA in r/r multiple myeloma show...
Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology. This data will be out sometime next year. I covered Arcellx ( ACLX ) at its IPO in January. Arcellx is a clinical stage biopharma developing cancer immunothera...
Arcellx press release ( NASDAQ: ACLX ): Q2 GAAP EPS of -$0.88. cash, cash equivalents, and marketable securities of $307.0 million For further details see: Arcellx GAAP EPS of -$0.88
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results PR Newswire -- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additi...
Arcellx ( NASDAQ: ACLX ) shares are down 9% in late Wednesday afternoon trading. Today marks the end of the company's IPO lock-up period. Volume is slightly above the daily average of ~305.2K. As of 325p ET, ~401.4K shares had traded hands. Arcellx is focused on ca...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...
For further details see: Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate
Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...